Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Zika Virus-Infected Mothers Face 13 Percent Risk Of Microcephaly

XTALKS VITALS NEWS

Microcephaly

This number was calculated based on Zika infection and birth defect data collected in French Polynesia – which experienced an outbreak of Zika between 2013 and 2014 – and Brazil.

Share this!

May 30, 2016 | by Sarah Massey, M.Sc.

A new study suggests that Zika virus infection in the first trimester of pregnancy, could result in a 13 percent risk of their child being born with the microcephaly birth defect. This number was calculated based on Zika infection and birth defect data collected in French Polynesia – which experienced an outbreak of Zika between 2013 and 2014 – and Brazil.

Cases of microcephaly – or children born with abnormally small heads – and Zika virus infection, have been on the rise in Brazil since 2015. Recently, the birth defect has been conclusively linked the virus, which is capable of crossing the placental barrier.

The study – which was published in the New England Journal Of Medicine – reported that women who become infected with the Zika virus beyond the first trimester, have a very low risk of giving birth to a baby with microcephaly.

According to researchers from Harvard University and the Centers for Disease Control and Prevention (CDC), they found “a strong association between the risk of microcephaly and infection risk in the first trimester, [but] a negligible association in the second and third trimesters. Although much remains unknown about the effects of [Zika] infection during pregnancy, population-level data from French Polynesia and [Brazil] reveal a clear association between first-trimester [Zika] infection and microcephaly risk.”



The researchers reported an estimated risk between 0.88 to 13.2 percent of birth defects due to Zika infection, in the first trimester of pregnancy. In the US, microcephaly is a relatively uncommon birth defect, with just 0.02 to 0.12 percent of all infants displaying characteristics of the condition.

As there is currently no vaccine against the Zika virus, officials are urging pregnant women to avoid becoming infected. The Zika virus is spread by the Aedes aegypti, so individuals in affected areas are being warned to eliminate standing water and wear protective clothing.

Since the Zika outbreak began in Brazil in 2015, 1,271 infants have been born with microcephaly. This birth defect results in brain damage including developmental delays, hearing problems and vision loss.


Keywords: Zika, MicrocephalyBirth Defect 


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.